• Atezolizumab plus bevacizumab safe, effective in malignant peritoneal mesothelioma

    3 days ago - By Healio

    Atezolizumab plus bevacizumab appeared well-tolerated and resulted in a 40% objective response rate among patients with malignant peritoneal mesothelioma, according to phase 2 study results published in Cancer Discovery.
    “Peritoneal mesothelioma is truly an orphan disease, with most of the attention in mesothelioma focused on pleural mesothelioma. There is little dedicated research toward this disease - we can probably count on one hand the number of trials that have been conducted for peritoneal mesothelioma,” Kanwal Raghav, MD, associate professor of gastrointestinal
    Read more ...